Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific ... Read More